Drug Trial Radar · NCT07185841
Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
198
Planned (sponsor's estimate)
Start
Jul 1, 2025
Primary completion
Jul 1, 2028
Study completion Jan 7, 2029
Sponsor
- Lead sponsor
- Fujian Haixi Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of Oral HX9428 tablets in patients with wet age-related macular degeneration(wAMD)
Conditions
- Wet Age-related Macular Degeneration (AMD)
Interventions
HX9428 tabletDrug
Subjects will receive HX9428 orally every day. The total treatment period is tentatively set at 25 weeks..
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I : Dose-Limiting Toxicity (DLT)Time frame: Week 4
- Phase II: Mean change of letters from baseline in Best Corrected Visual Acuity(BCVA)Time frame: week 25
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.